“Treatment-resistant” OCD is often mislabeled.
“Treatment-resistant” OCD is often mislabeled.
Many cases labeled resistant reflect inadequate SSRI dose or duration, or misdiagnosis; especially when intrusive obsessional images are mistaken for psychotic hallucinations.
True poor prognostic factors include early onset, long duration of untreated illness, and comorbid schizotypal traits.
Before escalating to antipsychotics or labeling failure, ensure the diagnosis is correct and that evidence-based treatment has truly been delivered.
Accurate assessment changes outcomes.
From my experience supporting individuals with OCD, I've seen how crucial it is to approach the diagnosis and treatment process with patience and precision. Many patients labeled as "treatment-resistant" have not been given sufficiently high SSRI doses or allowed enough time — often 12 weeks at a therapeutic dose — to experience meaningful improvement. This misunderstanding can prematurely push clinicians to escalate to antipsychotics or alternative therapies that might not address the core OCD symptoms. A particularly important issue I’ve noticed is the frequent misinterpretation of intrusive obsessional images as psychotic hallucinations. Unlike hallucinations, these obsessive images are ego-dystonic; patients recognize them as internally generated and distressing, which reflects intact insight. When this distinction is missed, patients may be misdiagnosed with psychotic disorders, leading to inappropriate treatment strategies. Additionally, poor prognostic factors like early onset of OCD symptoms, long untreated illness duration, and comorbid schizotypal traits can complicate treatment and reduce response to standard interventions. Understanding these prognostic indicators helps clinicians set realistic expectations and tailor treatment plans accordingly. Therefore, a comprehensive and evidence-based approach to assessment and therapy is essential. This includes confirming the diagnosis, optimizing SSRI dose and duration, and carefully distinguishing OCD symptoms from psychosis. With these steps in place, many individuals previously thought resistant can achieve meaningful symptom improvement and better quality of life. In sharing this perspective, I hope to encourage clinicians and patients alike to advocate for thorough, evidence-aligned treatment trials before labeling OCD as treatment-resistant.
